Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26139109
DOI
10.1002/art.39256
Knihovny.cz E-zdroje
- MeSH
- apoptóza účinky léků MeSH
- autofagie účinky léků MeSH
- biologické přípravky farmakologie MeSH
- fibroblasty účinky léků metabolismus patologie MeSH
- interleukin-1beta farmakologie MeSH
- interleukin-6 metabolismus MeSH
- kultivované buňky MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipopolysacharidy farmakologie MeSH
- osteoartróza metabolismus patologie MeSH
- protein TRAIL farmakologie MeSH
- revmatoidní artritida metabolismus patologie MeSH
- senioři MeSH
- synoviální membrána účinky léků metabolismus patologie MeSH
- thapsigargin farmakologie MeSH
- TNF-alfa antagonisté a inhibitory farmakologie MeSH
- tyrosinfosfatasa nereceptorového typu 2 metabolismus MeSH
- up regulace účinky léků MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické přípravky MeSH
- interleukin-1beta MeSH
- interleukin-6 MeSH
- lipopolysacharidy MeSH
- protein TRAIL MeSH
- PTPN2 protein, human MeSH Prohlížeč
- thapsigargin MeSH
- TNF-alfa MeSH
- tyrosinfosfatasa nereceptorového typu 2 MeSH
OBJECTIVE: To investigate the role of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in the pathogenesis of rheumatoid arthritis (RA). METHODS: Synovial tissue samples from patients with RA and patients with osteoarthritis (OA) were stained for PTPN2. Synovial fibroblasts were stimulated with tumor necrosis factor (TNF) and interleukin-1β (IL-1β), lipopolysaccharide (LPS), TRAIL, or thapsigargin. The expression of PTPN2 in synovial fibroblasts and peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and Western blotting. Cell death, the release of IL-6 and IL-8, and the induction of autophagy were analyzed after PTPN2 silencing. Methylated DNA immunoprecipitation analysis was used to evaluate DNA methylation-regulated gene expression of PTPN2. RESULTS: PTPN2 was significantly overexpressed in synovial tissue samples from RA patients compared to OA patients. Patients receiving anti-TNF therapy showed significantly reduced staining for PTPN2 compared with patients treated with nonbiologic agents. PTPN2 expression was higher in RA synovial fibroblasts (RASFs) than in OASFs. This differential expression was not regulated by DNA methylation. PTPN2 was further up-regulated after stimulation with TNF, TNF combined with IL-1β, or LPS. There was no significant difference in basal PTPN2 expression in PBMCs from patients with RA, ankylosing spondylitis, or systemic lupus erythematosus or healthy controls. Most interestingly, PTPN2 silencing in RASFs significantly increased the production of the inflammatory cytokine IL-6 but did not affect levels of IL-8. Moreover, functional analysis showed that high PTPN2 levels contributed to the increased apoptosis resistance of RASFs and increased autophagy. CONCLUSION: This is the first study of PTPN2 in RASFs showing that PTPN2 regulates IL-6 production, cell death, and autophagy. Our findings indicate that PTPN2 is linked to the pathogenesis of RA via synovial fibroblasts.
Center of Experimental Rheumatology University Hospital Zurich Zurich Switzerland
Schulthess Clinic Zurich Switzerland
Semmelweis University Budapest Hungary
Zurich Center for Integrative Human Physiology and University Hospital Zurich Zurich Switzerland
Citace poskytuje Crossref.org